Coherus BioSciences (CHRS) Tops Q2 EPS by 7c

Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Take-Two stock drops as GTA 6 leaks continue
• Lionel Messi says he will leave Argentine national team
• Wolfe Research on Protagonist Therapeutics (PTGX): 'We forecast peak sales of $2.9B in 2036'